Cerus Corporation (CERS) Q3 2023 Earnings Call Transcript

Cerus Corporation (NASDAQ:CERS) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET

Company Participants

Jessica Hanover – Vice President of Corporate Affairs

Obi Greenman – President & Chief Executive Officer

Vivek Jayaraman – Chief Operating Officer

Kevin Green – Chief Financial Officer

Conference Call Participants

Operator

Good day and thank you for standing by. Welcome to Cerus Corporation Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded.

I would now like to turn the call over to Jessica Hanover, Vice President of Corporate Affairs.

Jessica Hanover

Thank you, and good afternoon. I’d like to thank everyone for joining us today. As part of today’s webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the Investor Relations website at ir.serus.com.

With me on the call are Obi Greenman, Cerus’ President and Chief Executive Officer; Vivek Jayaraman, Cerus’s Chief Operating Officer; Kevin Green, Cerus’ Chief Financial Officer.

Cerus issued a press release today announcing our financial results for the third quarter ended September 30, 2023, and describing the company’s recent business highlights. You can access a copy of this announcement on the company website at www.cerus.com. I’d like to remind you that some of the statements we will make on this call related to future events and performance rather than historical facts and are forward-looking statements.

Examples of forward-looking statements include those related to our future financial and operating results, including our updated 2023 product revenue guidance, our Q4 adjusted EBITDA commitment and our expected expense, inventory and margin profile, expected future growth and our growth trajectory, expected future product sales, the availability and related timing of data from clinical trials

Read the full article here